The ImplantCenter has recently opened the brand-new operating room suited for more complex treatments. This comes alongside numerous additions such as the launch of the four cosy apartments to rest after treatments at the clinic and an implant education facility to expand their services further. These expansions are part of constant improvements that have been occurring for the last 15 years, alongside high quality service.
The area of the clinic has increased by ten-fold to approximately 1800 m2 during the years. Moreover, the oral surgery division was opened in 2015, so eight dental treatment rooms and four oral surgery rooms are now in place today. All of the surgery rooms can serve ambulatory oral surgery treatments. The ImplantCenter is unique in Hungarian private dentistry because they can implement more complex treatments in the framework of one-day oral surgery procedure. This is due to the big and fully equipped operating room opened in November 2017. As part of the service, the ImplantCenter offers one and two-bed private rooms with medical supervision to their patients after each surgery.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8274651-implantcenter-hungarian-dental-service/
TransCelerate BioPharma Inc., a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating research and development of innovative new therapies, has unveiled a new global campaign designed to help increase awareness of the growing need for clinical trial participants. The campaign, called “One Person Closer,” focuses on inspiring healthcare professionals (HCPs) to consider clinical research as a possibility for their patients, incorporate the topic into their daily practices, and have meaningful conversations with patients about opportunities to participate in clinical trials.
One Person Closer is designed to put a human face on research and development by sharing the personal stories of researchers, HCPs and patients who have contributed to clinical research and the development of medical breakthroughs. The photojournalist campaign aims to show doctors, nurses and other HCPs that they can help facilitate research that advances science and that may benefit their patients.
To view the multimedia release go to:
https://www.multivu.com/players/English/8268751-transcelerate-biopharma-one-person-closer/
Global specialty plastics provider Eastman demonstrates the dominant performance of next-generation material Eastman MXF221 copolyester as a disinfectant-ready polymer for safer healthcare environments at the Medical Design & Manufacturing (MD&M) West trade show in Anaheim, California, Feb. 6 to 8. The latest advancement in biocompatible medical-grade polymers for medical device housings and hardware, Eastman MXF221 offers unsurpassed chemical compatibility with stringent disinfectants used to combat healthcare-associated infections (HAIs) as well as improved durability and impact strength.
To view the multimedia release go to:
https://www.multivu.com/players/English/8261151-eastman-disinfectant-ready-polymer-mdm-west/
Medical, health, technology, healthcare, treatment, Richard Fechter, interview, trade show, MultiVu 8261151
Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the consumer launch of ageLOC LumiSpa, the first-of-its-kind, dual-action skin care device that treats and cleanses the skin. Following successful market previews, ageLOC LumiSpa is now available in the Americas and EMEA regions with launches to follow in North Asia, Greater China and Southeast Asia over the next three months.
ageLOC LumiSpa simultaneously delivers a skin-perfecting treatment and superior cleansing benefits to reveal smoother, softer skin after just one use. Now Nu Skin customers can be confident that their skin is clean, radiant and always ready for the perfect selfie or spontaneous photo moment.
To view the multimedia release go to:
https://www.multivu.com/players/English/8239151-nu-skin-care-device-ageloc-lumispa/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
GetWellNetwork®, the health care technology company that pioneered Interactive Patient Care™, introduced today a model for enhanced patient and family engagement that mirrors the fundamentals of precision medicine. Supported by The Patient’s Platform™ — a cross-continuum suite of integrated solutions, tools and strategies — Precision Engagement™ delivers uniquely personalized care guided by a person’s ability to take an active role in their health journey.
To view the multimedia release go to:
https://www.multivu.com/players/English/8151751-getwellnetwork-precision-engagement-the-patient-platform/
“Someone special at St. Jude would like to say hello,” this is what Guests at Chili’s® Grill & Bar Highland Springs restaurant heard after choosing to donate to St. Jude Children’s Research Hospital® during this year’s Create-A-Pepper campaign. It’s often difficult to connect how an add-on donation at the end of a meal or coloring a pepper while at Chili’s can have an impact on the kids at St. Jude, but over the past 15 years, each donation and pepper has added up to more than $64 million to support St. Jude’s mission of Finding cures. Saving children®.
This year, Chili’s is showing how a little action can create a big impact by continuing to connect those who care with those in need of care. ChiliHeads at Highland Springs in Beaumont, Calif. surprised everyday Guests with a special thank you for their donation to St. Jude. Guests came in expecting a normal dining experience and got something completely different. After a donation, Guests received a video call from a St. Jude survivor who personally shared their story and the difference each donation makes in ensuring that no family ever receives a bill.
To view the multimedia release go to:
https://www.multivu.com/players/English/8227251-chilis-st-jude-create-a-pepper/
Based on an original story by Roberto Stopello and written by Indira Páez, the new season of the Super Series™ unfolds within the painful context of the undocumented immigrants who cross the border from Mexico to the United States in search of the American Dream. “Señora Acero, La Coyote” continues the story of Vicenta Acero (Carolina Miranda), a strong woman who has carved a path for herself in a male-dominated world and fights for better treatment of the many immigrants who struggle to cross one of the world’s longest borders. In the new season, La Coyote faces enemies on both sides of the law who are out for revenge and to destroy the Acero Quintanilla dynasty.
To view the multimedia release go to:
https://www.multivu.com/players/English/8202051-telemundo-senora-acero-la-coyote/
A new online resource is now available to help people recognize and find high quality care for alcohol use disorder, which affects more than 15 million adults in the United States. The Alcohol Treatment Navigator, designed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, is a comprehensive, yet easy-to-use tool to help individuals and their loved ones navigate the often-complicated process of choosing treatment for alcohol problems. With many treatment options available, the navigator makes the search easier by telling them what they need to know - and what they need to do – to find appropriate, quality care.
“We developed this tool to help address the alcohol ‘treatment gap,’” said NIAAA Director George F. Koob, Ph.D. “In any given year, less than 10 percent of individuals diagnosed with alcohol use disorder receive treatment, and many of them do not receive the type of care that best fits their needs. A big reason for that, we believe, is that people with alcohol use disorder often don’t know where to turn for help. The Alcohol Treatment Navigator offers a comprehensive strategy to help people search for professionally-led, evidence-based alcohol treatment, which should improve their chances for success.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8179051-niaaa-alcohol-treatment-navigator/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that NFL analyst and philanthropist, Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, will serve as a brand ambassador for BOTOX® Cosmetic.
Harnessing Sanders’ trademark swagger, style and humor, Allergan also released two videos featuring Sanders sharing how he addressed his moderate to severe frown lines and crow’s feet with BOTOX® Cosmetic and showing men everywhere how the treatment may be right for them as well.
To view the multimedia release go to:
https://www.multivu.com/players/English/8174251-allergan-deion-sanders-botox/
Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
A new survey commissioned by The Leukemia & Lymphoma Society (LLS) reveals more than four in five adults (82%) are surprised that blood cancers are the third leading cancer killer of Americans. Further, nearly four in five adults (78%) are surprised that acute lymphocytic leukemia (ALL) is the most common cancer in children and young adults under age 20.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128551-lls-blood-cancer-awareness-month/